APMD (Apnimed) Short Percentage of Float

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

APMD Apnimed Inc APMD
8 GF Score
Price $25.00
View Full Analysis

What is Apnimed Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

APMD vs : Short Percentage of Float Comparison

For the Biotechnology subindustry, Apnimed's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apnimed Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apnimed's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Apnimed's Short Percentage of Float falls into.


APMD
8GF Score
Apnimed Inc APMD
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apnimed Business Description

Comparable Companies
Address 39 John F. Kennedy Street, 4th Floor, Cambridge, MA, USA, 02138
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
8GF Score

Get the complete analysis for APMD

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.00
Price